Angiotensin (Ang) II, the main component of the reninangiotensin system, plays an important role in the pathogenesis of cardiovascular diseases including hypertension. 1 Ang II-induced hypertension is due to its action in the subfornical organ (SFO) of circumventricular organs resulting in increased oxidative and endoplasmic reticulum (ER) stress and activity of the sympathetic nervous system. [2] [3] [4] There is a substantial body of evidence that increased reactive oxygen species (ROS) production and activation of immune cells mediate Ang II-induced hypertension and associated pathogenesis. [5] [6] [7] [8] Ang II also increases the activity of cytosolic phospholipase A 2 (cPLA 2 ) resulting in arachidonic acid (AA) release from tissue phospholipids. 9,10 AA is metabolized by cyclooxygenase (COX), lipoxygenase, and cytochrome P450A into various eicosanoids with prohypertensive and antihypertensive effects. 11-13 Prostaglandin (PG) E2, by stimulating EP1 and EP3 receptors, 14 and thromboxane A2, 11 12, 13, 15, 16 by their vascular actions, exert prohypertensive effects. On the other hand, PGE2 through stimulation of EP2 and EP4 receptors, 14,17 PGI2, 11 and epoxyeicosatrienoic acids 13,18 produce vasodepressor effects. One or more of the eicosanoids contribute to Ang II-induced hypertension. [19] [20] [21] [22] Ang II-salt hypertension is also dependent on COX-1 activity. 23 Intracerebroventricular
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Angiotensin (Ang) II, the main component of the reninangiotensin system, plays an important role in the pathogenesis of cardiovascular diseases including hypertension. 1 Ang II-induced hypertension is due to its action in the subfornical organ (SFO) of circumventricular organs resulting in increased oxidative and endoplasmic reticulum (ER) stress and activity of the sympathetic nervous system. [2] [3] [4] There is a substantial body of evidence that increased reactive oxygen species (ROS) production and activation of immune cells mediate Ang II-induced hypertension and associated pathogenesis. [5] [6] [7] [8] Ang II also increases the activity of cytosolic phospholipase A 2 (cPLA 2 ) resulting in arachidonic administration of PGE2 increases sympathetic activity, vasopressin release, and blood pressure (BP), 24 and the hypothalamic paraventricular excitation and sympathetic activation, via EP3 receptors. 25 Injection of PGE2 into the rostral ventrolateral medulla also causes sympathoexcitation and pressor response via the EP3 receptor. 26 These observations suggest that the release of AA by cPLA 2 , the rate-limiting step in the synthesis of eicosanoids, could be critical for Ang II-induced ROS production and hypertension.
Several types of mammalian cPLA 2 enzymes have been identified; 27 however, group IV cPLA 2 shows high selectivity for AA-containing phospholipids. 27, 28 cPLA 2 consists of six isoforms (cPLA 2 α, -β, -γ, -δ, -ε, and -ζ) with only 30% homology, tissue distribution, and enzymatic activity. 28 In a previous study, we showed that the selective cPLA 2 α gene disruption prevented Ang II-induced increase in urinary levels of eicosanoids, hypertension, and associated cardiovascular, renal dysfunction and inflammation, suggesting that prohypertensive eicosanoids generated from AA mediate Ang II-induced hypertension. 29, 30 However, the site of eicosanoids produced by group IV cPLA 2 α, which mediate Ang II-induced hypertension, is not known. Since numerous tissues including cardiovascular, renal, brain, and immune cells produce eicosanoids that exert their effect locally, these should be formed from AA released by cPLA 2 α and act at the site of action of Ang II.
PLA 2 is distributed in several regions of the brain, 31 and Ang II increases expression of PLA 2 in the organum vasculosum of the lamina terminalis, paraventricular nucleus (PVN), nucleus of the solitary tract, and middle cerebral artery. 32 The demonstration that Ang II-induced oxidative stress and hypertension is mediated via the COX-1-derived metabolite PGE2 via EP1 receptor in the SFO 33 raises the possibility that cPLA 2 α in the SFO might be critical for the action of Ang II to increase oxidative stress and BP. To test this hypothesis, we examined the localization and the effect of cPLA 2 α depletion in the SFO by transduction with adenovirus (Ad)-green fluorescence protein (GFP)-cPLA 2 α short hairpin (sh) RNA (Ad-cPLA 2 α shRNA). We also examined its reconstitution in knockout (cPLA 2 α −/− ) mice by transduction with Ad-enhanced cyan fluorescence protein (ECFP)-cPLA 2 α DNA (Ad-cPLA 2 α DNA) in the SFO. We then examined the effect of these probes on Ang II-induced hypertension and associated pathogenesis in mice. Our results show that depletion of cPLA 2 α in the SFO prevents Ang II-induced hypertension, ROS and ER stress, and associated pathogenesis, while expression of cPLA 2 α in cPLA 2 α −/− mice restores these deleterious effects of Ang II.
MATERIALS AND METHODS
Details for Materials and Methods section are in the online-only Data Supplement.
Animal experiments
All animal experiments were performed using protocols approved by the University of Tennessee Health Science Center Institutional Animal Care and Use Committee according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Experiments were conducted in 8-to 10-week-old, 20-to 25-g body weight, wild-type (cPLA 2 α +/+ ), and cPLA 2 α gene disrupted homozygous (cPLA 2 α −/− ) male mice on BALB/c background. Ang II (700 ng/kg/min) or saline (vehicle) was infused for 14 days with micro-osmotic pumps implanted subcutaneously. Systolic BP (SBP) was measured by the noninvasive tail-cuff method, or mean arterial pressure (MAP) daily by radio telemetry. However, 2 to 3 out of 6 cPLA 2 α −/− BALB/c mice implanted with radio transmitters did not survive more than 8 to 10 days. We did not encounter this problem in male C57BL/6 mice. Therefore, we first confirmed the BP measurements recorded by the tail-cuff method in the male C57BL/6 mice to that obtained in BALB/c mice and then used cPLA 2 α −/− mice on the C57BL/6 background to further confirm BP measurements by radio telemetry.
Statistical analysis
One or 2-way analysis of variance was used to analyze the data, Tukey's post hoc test for multiple comparisons, and student's t-test to compare the difference between 2 groups. The values obtained from at least 3 to 5 different experiments were expressed as the mean ± SEM, P <0.05 was considered statistically significant. Ang II is known to cause cardiac and renal fibrosis. 29, 30 To determine if the alteration in cPLA 2 α expression in the SFO also affects the action of Ang II on cardiac and renal fibrosis, we examined the accumulation of collagen in these tissues in BALB/c mice. cPLA 2 α gene disruption in the SFO of cPLA 2 α +/+ mice by transduction with Ad-cPLA 2 α shRNA but not its Ad-Scr shRNA control infused with Ang II minimized accumulation of collagen in the heart and kidney (Supplementary Figure S4A and B). cPLA 2 α, but it increased the cPLA 2 activity, measured by phospho-cPLA 2 immunoreactivity in the SFO transduced with Ad-cPLA 2 α DNA, but not Ad-GFP DNA in BALB/c mice (Figure 2c and d) . cPLA 2 α mRNA expression in the PVN, heart, and kidney that was absent in cPLA 2 α −/− BALB/c, was not altered by transduction of the SFO with Ad-GFP DNA or Ad-cPLA 2 α DNA during infusion of Ang II (Supplementary Figure S5C-E) .
We also determined the effect of Ang II on collagen accumulation in the heart and kidney of BALB/c cPLA 2 α −/− mice transduced with Ad-cPLA 2 α DNA and Ad-GFP DNA in the SFO, and found collagen accumulation in the former but not the latter group of mice (Supplementary Figure  S7A and B) . These studies were conducted in BALB/c mice that were infused with Ang II or its vehicle for the measurement of BP as described above. Infusion of Ang II also stimulated the production of ROS as indicated by enhanced 2-hydroxyethidium fluorescence in the SFO generated after staining with dihydroethidium as described, 4 in cPLA 2 α +/+ mice but not in cPLA 2 α −/− mice (Figure 3a and b) . Transduction of the SFO with Ad-cPLA 2 α shRNA but not its Ad-Scr shRNA inhibited dihydroethidium staining (Figure 3c to increase dihydroethidium staining, whereas transduction with Ad-cPLA 2 α DNA, but not Ad-GFP DNA in the SFO of these mice restored the effect of Ang II to increase dihydroethidium staining (Figure 3e and f) . Figure S1A and B) . To determine if partial cPLA 2 α gene disruption reduces Ang II-induced increase in BP, we examined its effect in heterozygous cPLA 2 α (cPLA 2 α +/− ) C57BL/6 male mice. Ang II (700 ng/kg/min) increased SBP measured by tailcuff in cPLA 2 α +/+ but not cPLA 2 α +/− C57BL/6 male mice (Supplementary Figure S8) . cPLA 2 α mRNA expression in the SFO, heart, and kidney of C57BL/6 cPLA 2 α +/− mice was lower (60-80%) than in C57BL/6 cPLA 2 α +/+ mice (Supplementary Figure S9) .
DISCUSSION
The major findings of this sudy are that SFO is the principal site of action of cPLA 2 α in mediating the action of Ang II: (i) to increase BP; (ii) to stimulate ROS production and ER stress in the SFO, and (iii) to cause cardiac and renal fibrosis. These findings are based on our demonstration that cPLA 2 α selectively releases AA from tissue phospholipids, 27, 28 is expressed in the SFO, and that Ang II increased cPLA 2 activity, as determined by its phosphoimmunoreactivity without altering its expression. However, Ang II has been shown to increase expression of phospholipase A 2 in the organum vasculosum of the lamina terminalis, PVN, nucleus of the solitary tract, and middle cerebral artery of the rat. 32 Whether this increase in phospholipase A 2 expression by Ang II in these tissues represents primarily increased expression of cPLA 2 α, or other isoforms of phospholipase A 2 is not known. We have previously reported that Ang II increases BP, and sympathetic outflow as determined from heart rate variability by power spectral analysis in cPLA 2 α +/+ but not cPLA 2 α −/− BALB/c mice. 29 Our demonstration that cPLA 2 α gene disruption in the SFO by Ad-cPLA 2 α shRNA, but not its Ad-Scr shRNA, reduced cPLA 2 α expression and phospho-cPLA 2 immunoreactivity and prevented Ang II-induced increase in BP in cPLA 2 α +/+ BALB/c and C57BL/6 mice, suggests that cPLA 2 α in the SFO is critical for Ang II-induced hypertension. Although Ang II 700 ng/kg/min used in this study would be expected to cause the increase in BP by its direct vascular action but it appears that cPLA 2 α in the SFO is primarily responsible for this effect of Ang II. Further supporting this conclusion was our finding that in cPLA 2 α −/− BALB/c and C57BL/6 mice, reconstitution of cPLA 2 α in the SFO by transduction with Ad-cPLA 2 α DNA but not Ad-GFP DNA increased cPLA 2 α expression and phospho-cPLA 2 immunoreactivity, and restored the effect of Ang II to increase BP. That cPLA 2 α protein formed by transduction with Ad-cPLA 2 α DNA, but not Ad-GFP DNA is capable of releasing AA has been confirmed in vascular smooth muscle cells. 34 The decrease in the expression of cPLA 2 α in the SFO transduced with Ad-Scr shRNA in cPLA 2 α +/+ mice, and the increase with Ad-cPLA 2 α DNA in cPLA 2 α −/− mice was selective because its expression in the PVN, heart and kidney were not altered in these mice. Ang II stimulates ROS production and ER stress in the SFO that leads to an increase in BP, 3, 4 most likely by increasing sympathetic activity. 2 The increase in BP produced by Ang II 600 ng/kg/min, which is comparable to that obtained in the present study by 700 ng/ kg/min of this peptide, is prevented by intracerebral ventricle administration of superoxide scavenger Ad-CuZn superoxide dismutase. 4 Since (i) depletion of cPLA 2 α by Ad-cPLA 2 α shRNA in the SFO of cPLA 2 α +/+ mice reduced, and (ii) expression of cPLA 2 α by transduction with Ad-cPLA 2 α DNA in cPLA 2 α −/− BALB/c mice restored Ang II-induced ROS production and ER stress, this suggests that cPLA 2 α expression and activity mediates the effect of Ang II on ROS production and ER stress. Whether alteration in cPLA 2 α activity by Ang II in SFO also affects the ROS production and ER stress in PVN and rostral ventrolateral medulla remains to be determined. Ang II is known to produce cardiac and renal fibrosis, which is dependent on prohypertensive eicosanoids generated by activation of cPLA 2 α. 29, 30 Our demonstration that Ang II-induced cardiac and renal fibrosis, as indicated by collagen accumulation, was minimized by depletion of cPLA 2 α in the SFO by transduction with Ad-cPLA 2 α shRNA in cPLA 2 α +/+ BALB/c mice suggests that cPLA 2 α activation in the SFO contributes to this action of Ang II. Supporting this view was our observation that reconstitution of cPLA 2 α by Ad-cPLA 2 α DNA in cPLA 2 α −/− BALB/c mice caused Ang II to produce cardiac and renal fibrosis. Whether attenuation of Ang II-induced cardiac and renal fibrosis caused by decreased expression of cPLA 2 α by Ad-cPLA 2 α shRNA in the SFO of cPLA 2 α +/+ mice and restoration of fibrosis in these tissues by expression of cPLA 2 α by Ad-cPLA 2 α DNA in cPLA 2 α −/− mice, which could be due to changes in BP and/or sympathetic activity, remains to be determined. cPLA 2 α activation by Ang II releases AA that is metabolized by COX, lipoxygenase, and cytochrome P450A into eicosanoids with prohypertensive and antihypertensive effects. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Previously, we reported that prohypertensive eicosanoids generated by cPLA 2 α activation contributed to Ang II-induced hypertension and associated cardiac and renal pathogenesis. 29, 30 COX-1 inhibitor SC560 minimized Ang II-salt-induced hypertension which is associated with the increased sympathetic activity. 32 Decrease in COX-2 expression by IL-10 in PVN is related to reduced neuronal sympathetic excitation in heart failure in rats after myocardial infarction. 35 On the other hand, proinflammatory cytokines stimulate COX-2 expression in perivascular macrophages, 36 and when injected in the SFO increase BP, heart rate, and renal sympathetic activity. 37 Therefore, Ang II via production of proinflammatory cytokines could increase COX activity and PGE2 synthesis. Reduction in COX-1 and COX-2 expression by their respective siRNA in PVN also reduces deoxycorticosterone-induced hypertension. 38 COX-generated AA metabolite PGE2 injected into the cerebroventricular system 24, 25 or rostral ventrolateral medulla 26 increases BP and sympathetic activity via EP3 receptors, respectively. 25, 26 Ang II-induced increase in BP is inhibited in both EP1 and EP3 receptor knockout mice or by EP1 and EP3 receptor antagonists. 19, 21 PGE2 generated by COX-1 in the SFO via the EP1 receptor is required for ROS generation and hypertension caused by Ang II. 33 AA-metabolizing enzymes are constitutively active, and the rate-limiting step in the production of eicosanoids is the availability of AA. Therefore, cPLA 2 α activation by Ang II in the SFO appears to be critical for AA release resulting in the production of PGE2, and generation of ROS and ER stress that increases BP and results in cardiac and renal fibrosis. The contribution in Ang II-induced hypertension of cPLA 2 α in the PVN and rostral ventrolateral medulla where PGE2 via EP3 receptors increases BP 25, 26 remains to be investigated and is one of the limitations of the present study. Like in our study in cPLA 2 α −/− mice, the COX1 or EP1 receptor gene disruption or the central administration of their pharmacological inhibitors attenuated the increase in BP produced byAng II (600 ng/kg/min) 33 that was comparable to that obtained in the present study. At present, we have no explanation how the central cPLA 2 α/COX1/EP1 receptor in SFO masks the direct vasconstrictor effect of Ang II. Further studies are required to determine if alteration in cPLA 2 α/COX/EP receptors in SFO and other brain areas also prevent the effect of bolus injections or short-term infusion of Ang II.
An important finding in our study was that Ang II also failed to increase BP in the partially cPLA 2 α gene-disrupted mice (cPLA 2 α +/− ) expressing reduced cPLA 2 α mRNA in the heart, kidney, and SFO in C57BL/6 mice. These observations further support the critical role of cPLA 2 α in Ang II-induced hypertension. Further studies on different levels of cPLA 2 α expression or its copy number in the SFO and other tissues should allow the determination of its relationship to BP in various models of hypertension and associated pathogenesis. cPLA 2 α gene disruption also prevented hypertension produced by the inhibitor of nitric oxide synthesis, L-NGnitroarginine methyl ester, 39 that is dependent on Ang II. 40 Our preliminary data obtained in C57BL/6 mice showed that cPLA 2 α gene disruption abolished deoxycorticosteroneacetate-salt-induced hypertension and associated cardiac and renal fibrosis (C Y Song and K U Malik, unpublished results).
In conclusion, this study demonstrates that cPLA 2 α in the SFO is crucial in mediating the effect of systemic Ang II to cause ROS production and ER stress and hypertension, most likely by releasing AA and metabolizing it via COX producing PGE2. Our finding that the partial cPLA 2 α gene disruption (cPLA 2 α +/− mice) also prevented Ang II-induced hypertension supports the notion that cPLA 2 α activation is pivotal for the development of Ang II-induced hypertension. Therefore, development of selective orally active inhibitors of cPLA 2 α could be useful in the treatment of hypertension and its pathogenesis.
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